Love and a Lab Coat: One Couple’s Quest to Treat Alzheimer Disease
June 20th 2021Luca Giliberto, MD, PhD, and Cristina d’Abramo, PhD, share more than a marriage: After years of research, their combined efforts to develop a passive immunotherapy for Alzheimer disease have earned them a $2 million grant from the National Institutes of Health.
Managing the Intricacies and Age-Specific Challenges of Pediatric Multiple Sclerosis
June 17th 2021Two experts in pediatric MS care, Lauren B. Krupp, MD, and Tanuja Chitnis, MD, offer tips and insight on the diagnosis of the disease and the specific challenges faced by patients stemming from their own clinical experience.
ADAPT Trial of Efgartigimod and its Potential in gMG: James F. Howard, MD
June 16th 2021The Distinguished Professor of Neuromuscular Disease at UNC School of Medicine discussed the findings of the ADAPT trial and the promise efgartigimod has shown to be an effective agent for generalized myasthenia gravis.
Myostatin Inhibition in Amyotrophic Lateral Sclerosis
June 16th 2021ALS has only recently been associated with causative or disease-modifying mutations in 20 genes that encode proteins with diverse functions, with promising therapeutic targets including proteins in pathways that regulate protein homeostasis.
Integrating Advanced Practice Clinicians Into Neurology: Calli L. Cook, NP, DNP
June 16th 2021The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why a cultural shift is needed to incorporate APCs into the neurology space and thus improve multidisciplinary care.
Do We Finally Have a Useful “Sed Rate” for Multiple Sclerosis?
June 15th 2021All agree that having a simple, standardized serum biomarker to measure disease activity would offer the greatest utility in treating a medical condition such as MS, which now has a variety of graded therapies available.